

# AAX Biotech announces collaboration with Vascurie to advance high-throughput antibody characterization for neuro-oncology therapies

Biotech company AAX Biotech, a leading innovator in technologies for antibody-based medicines, today announced a new collaboration with Vascurie, a company developing therapeutics in neuro-oncology. Through a high-throughput program, AAX Biotech will leverage its Seqitope® platform and automation infrastructure to accelerate antibody characterization, driving faster, data-driven insights across drug discovery and development.



AAX Biotech develops technologies that advance antibody therapeutic development, with a focus on high-resolution epitope mapping and antibody engineering. These capabilities enable partners to generate deeper molecular insights and support more informed decision-making across antibody development.

As part of the collaboration, AAX Biotech will apply Seqitope®, its proprietary technology for high-resolution, high-throughput epitope mapping, to characterize Vascurie’s antibody candidates against CD93, a novel drug target in neuro-oncology. Seqitope® combines amino acid-level epitope insights with the ability to process large numbers of antibodies in parallel, enabling rapid and data-rich decision-making during therapeutic development.

To address the increasing demand for high-throughput analyses that accelerate drug discovery, AAX Biotech recently installed an advanced automation robot designed to enable large-scale Seqitope® workflows, while significantly increasing speed and scalability. The collaboration with Vascurie will be executed as a high-throughput project, fully utilizing these expanded capabilities.

“The ability to generate high-resolution epitope data at true high throughput represents a significant advance for antibody discovery and development,” says Daniel X. Johansson, CEO and CSO of AAX Biotech. “With Seqitope® and our new robotic platform, we can now characterize up to 100 antibodies in parallel, providing Vascurie with rapid, high-quality insights to support their neuro-oncology programs.”

“This collaboration strategically accelerates our initiative to develop monoclonal antibodies targeting CD93. By enabling multiplex parallel analysis of our proprietary molecules, this comprehensive approach will rapidly generate critical insights into the molecular pharmacology of our lead candidate, VDL-309, and other antibodies with distinct biomedical properties,” says Jonas Ekblom, CEO of Vascurie. “This dataset generated together with AAX Biotech will allow Vascurie to de-risk the development and optimize the selection of backup compounds,” he continues.

**For more information, please contact:**

Maria Lisa Knudsen, CBO, AAX Biotech

+46 72 939 5018

[maria.knudsen@aaxbiotech.com](mailto:maria.knudsen@aaxbiotech.com)

Jonas Ekblom, CEO, Vascurie

+46 736 777 540

**About AAX Biotech AB**

AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope® and Opti-mAb®, that enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit [aaxbiotech.com](http://aaxbiotech.com) to learn more and follow [AAX Biotech on LinkedIn](#).

**About Vascurie**

Vascurie AB is a biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) tumors. The company's lead candidate, VDL-309, is a monoclonal antibody targeting the cell surface protein CD93. By modulating the vascular environment around aggressive brain tumors, VDL-309 represents a new therapeutic approach for treating high-grade gliomas and brain metastases. The project is advancing through preclinical studies, with an IND/CTA submission targeted for 2027. Vascurie's strategy is underpinned by pioneering research from Uppsala University and reflects its commitment to translating innovative science into treatments that improve outcomes for patients with aggressive CNS cancers.